lucius卢修斯 兰泽替尼拉泽替尼Lazertinib全球首仿

兰泽替

美国FDA批准上市产品,疗效确切

另译为
拉泽替尼

卢修斯制药(老挝)有限公司出品

Lazertinib

老挝国家食药监局批准上市
老挝国家药检所检测认证
全球首仿

Conposidoa:
Exch film-coated tablet contains Lazertinib mesylate
0y drate 95.86 mg equivalent to Lazertinib .......

LUCIUS

Indicatiar:

PHARMACEUTICALS

estiants with locally sdsanced or metastafic mon-small
ell lung cancer (NSCLC] xith egidermal growth facte

非小细胞肺癌

19 deletions or eson 21 L858R
substtation mutations. as detected bu an FD A-annroued

Desage and Use:

LuciLazer

uacceptabletoricity00r

Aom nister LiciLazer any time prior to ams vantama

Lazertinib Tablets

wlet given oa the sime day.
Alolte amivantamab prescribing information for

Rx Only

FDA批准

senous thromhoembn len atant UTE)
con palanf prophy latis to preven
tromboemholic events (VTE) forthe first four
months of treatment
Starage: in a dry place ond store nt 30°C to 25°C

80mg

Keep medicins ost of reach of Chuldren. Do not
ALKAGE INSLNI
Manufactured and Marketed by:
LUCIUS
Thongmang village, Xaythany distric

权威认证

Vientiane Capital, Laos
Warning : To be sold by retail on prescrictie
cians onty, and as dirested

60 Tablets

口碑质量

适应症:
1、与Amivantamab联合用于一线治疗表皮生长因子受体(EGFR)外显子19
缺失或外显子21L858R替代突变的局部晚期或转移性非小细胞肺癌
(NSCLC)成年患者。
2、亦可单独服用,用于治疗表皮生长因子受体(EGFR)外显子19缺失或外显
子21L858R替代突变的局部晚期或转移性非小细胞肺癌(NSCLC)成年患者。
推荐剂量:
1、兰泽替尼的推荐剂量为每日一次,每次240mg,持续治疗直至病情进展或
出现不可接受的毒性。
2、可与Amivantamab同服或空腹服用,关于Amivantamab的推荐剂量,请
查阅其详细说明书。
3、在治疗的前四个月内,应进行抗凝预防,以预防静脉血栓栓塞事件(VTE)。